Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 100

1.

An Intriguing Family with Type 2 Diabetes Mellitus and Complete Heart Block.

Agarwal G, Singh SK.

Indian J Endocrinol Metab. 2017 Sep-Oct;21(5):784-786. doi: 10.4103/ijem.IJEM_449_16.

2.

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.

Pollack PS, Chadwick KD, Smith DM, Billger M, Hirshberg B, Iqbal N, Boulton DW.

Cardiovasc Diabetol. 2017 Sep 13;16(1):113. doi: 10.1186/s12933-017-0595-6. Review.

3.

Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure.

Swoboda PP, McDiarmid AK, Erhayiem B, Ripley DP, Dobson LE, Garg P, Musa TA, Witte KK, Kearney MT, Barth JH, Ajjan R, Greenwood JP, Plein S.

J Am Heart Assoc. 2017 Jul 17;6(7). pii: e005539. doi: 10.1161/JAHA.117.005539.

4.

Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes.

González N, Moreno-Villegas Z, González-Bris A, Egido J, Lorenzo Ó.

Cardiovasc Diabetol. 2017 Apr 4;16(1):44. doi: 10.1186/s12933-017-0528-4. Review.

5.

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.

Lorenz M, Lawson F, Owens D, Raccah D, Roy-Duval C, Lehmann A, Perfetti R, Blonde L.

Cardiovasc Diabetol. 2017 Jan 13;16(1):6. doi: 10.1186/s12933-016-0490-6. Review.

6.

Effectiveness of computerized point-of-care reminders on adherence with multiple clinical recommendations by primary health care providers: protocol for a cluster-randomized controlled trial.

Méndez Boo L, Coma E, Medina M, Hermosilla E, Iglesias M, Olmos C, Calero Muñoz S, Caro Mendivelso J.

Springerplus. 2016 Sep 7;5(1):1505. doi: 10.1186/s40064-016-3124-2. eCollection 2016.

7.

Glucagon and heart in type 2 diabetes: new perspectives.

Ceriello A, Genovese S, Mannucci E, Gronda E.

Cardiovasc Diabetol. 2016 Aug 27;15(1):123. doi: 10.1186/s12933-016-0440-3. Review.

8.

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.

Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA.

Diabetes Care. 2016 May;39(5):717-25. doi: 10.2337/dc16-0041.

9.

Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway.

Korkmaz-Icöz S, Al Said S, Radovits T, Li S, Brune M, Hegedűs P, Atmanli A, Ruppert M, Brlecic P, Lehmann LH, Lahrmann B, Grabe N, Yoshikawa Y, Yasui H, Most P, Karck M, Szabó G.

Cardiovasc Diabetol. 2016 May 6;15:75. doi: 10.1186/s12933-016-0383-8.

10.

Type 2 Diabetes Dysregulates Glucose Metabolism in Cardiac Progenitor Cells.

Salabei JK, Lorkiewicz PK, Mehra P, Gibb AA, Haberzettl P, Hong KU, Wei X, Zhang X, Li Q, Wysoczynski M, Bolli R, Bhatnagar A, Hill BG.

J Biol Chem. 2016 Jun 24;291(26):13634-48. doi: 10.1074/jbc.M116.722496. Epub 2016 May 5.

11.

Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.

Toh S, Hampp C, Reichman ME, Graham DJ, Balakrishnan S, Pucino F, Hamilton J, Lendle S, Iyer A, Rucker M, Pimentel M, Nathwani N, Griffin MR, Brown NJ, Fireman BH.

Ann Intern Med. 2016 Jun 7;164(11):705-14. doi: 10.7326/M15-2568. Epub 2016 Apr 26.

12.

Insulin Signaling and Heart Failure.

Riehle C, Abel ED.

Circ Res. 2016 Apr 1;118(7):1151-69. doi: 10.1161/CIRCRESAHA.116.306206. Review.

13.
14.

Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus.

Liu JH, Chen Y, Yuen M, Zhen Z, Chan CW, Lam KS, Tse HF, Yiu KH.

Cardiovasc Diabetol. 2016 Feb 3;15:22. doi: 10.1186/s12933-016-0333-5.

15.

Glucose uptake and lipid metabolism are impaired in epicardial adipose tissue from heart failure patients with or without diabetes.

Burgeiro A, Fuhrmann A, Cherian S, Espinoza D, Jarak I, Carvalho RA, Loureiro M, Patrício M, Antunes M, Carvalho E.

Am J Physiol Endocrinol Metab. 2016 Apr 1;310(7):E550-64. doi: 10.1152/ajpendo.00384.2015. Epub 2016 Jan 26.

16.

Effects of exercise training on carotid intima-media thickness in patients with type 2 diabetes and coronary artery disease. Influence of carotid plaques.

Byrkjeland R, Stensæth KH, Anderssen S, Njerve IU, Arnesen H, Seljeflot I, Solheim S.

Cardiovasc Diabetol. 2016 Jan 22;15:13. doi: 10.1186/s12933-016-0336-2.

17.

Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy.

Jia G, DeMarco VG, Sowers JR.

Nat Rev Endocrinol. 2016 Mar;12(3):144-53. doi: 10.1038/nrendo.2015.216. Epub 2015 Dec 18. Review.

18.

Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages.

Tate M, Robinson E, Green BD, McDermott BJ, Grieve DJ.

Basic Res Cardiol. 2016 Jan;111(1):1. doi: 10.1007/s00395-015-0518-1. Epub 2015 Nov 23.

19.

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.

Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Pieters IC, Cahen DL, Diamant M, van Raalte DH.

BMJ Open. 2015 Nov 19;5(11):e009579. doi: 10.1136/bmjopen-2015-009579.

20.

Supplemental Content

Loading ...
Support Center